Formulation and Evaluation of Bilayer Tablets of Atenolol and Amlodipine for the Treatment of Hypertension

The current study concentrated about development and the in vitro assessment of a bilayer tablet with a particular dosage containing two well-known hypertension medications, amlodipine and atenolol. Using varying percentages of the sodium starch glycolate and polyvinylpyrrolidone as super-disintegrants to promote blood pressure-lowering activity, tablets were developed to release atenolol. (A1-A4) immediately. The tablets were also structured to sustain the release of amlodipine (B1-B4) by changing the proportion of hydroxypropyl methylcellulose (HPMC) and anhydrous DCP for prolonged activity. The United States Pharmacopoeia (USP) guidelines were referred to evaluate thechemical and physical propertiesof formulations. The results indicated that the best immediate release formulation exhibited 100% dissolution after 45 minutes later, along with other tablet characteristics such as hardness, disintegration time, and powder flowing properties. Nonetheless, disintegration (100% after twenty four hours with consistent release) and some tablet features are demonstrated by the best sustained release formulation. After formulation adjustment, the atenolol as well as amlodipine components were both effectively compressed as a bilayer tablets, and compression properties were determined. After 45 minutes, the bilayer tablet's atenolol was reported to be 100% released in 0.1 N HCl media, but amlodipine was 100% released in phosphate buffer medium after twenty four hours.